Patents Assigned to Pfizer
  • Compounds useful in therapy
    Publication number: 20020099216
    Abstract: There is provided a compound of formula I, 1
    Type: Application
    Filed: March 27, 2002
    Publication date: July 25, 2002
    Applicant: Pfizer Inc.
    Inventors: Stephen Paul Gibson, Ivan Tommasini, David Morris Gethin, Richard Edward Armer
  • Aralkyl and aralkylidene heterocyclic lactams and imides
    Patent number: 6423708
    Abstract: The present invention relates to compounds of the formula I wherein R1, R2, R3, X, Y and the dashed line are as defined in the specification, to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use as psychotherapeutic agents.
    Type: Grant
    Filed: December 8, 2000
    Date of Patent: July 23, 2002
    Assignee: Pfizer INC
    Inventors: Megan Ann Gibbs, Harry Ralph Howard, Jeffrey Scott Sprouse, Joel Barry Schachter, Phillip Branch Chappell
  • Inhibiting oxidative degradation of pharmaceutical formulations
    Patent number: 6423351
    Abstract: The invention provides methods for inhibiting oxidative degradation of pharmaceutical formulations comprising at least one oxidation-susceptible active drug ingredient which methods comprise adding an oxidation-inhibiting amount of a ferrous ion source, preferably in the form of a pharmaceuticalexcipient, to the formulation. The invention further provides pharmaceutical formulations comprising at least one oxidation-susceptible active drug ingredient and an oxidation-inhibiting amount of a ferrous iron source, preferably in the form of a pharmaceuticalexcipient. The invention still further provides for the use of a ferrous ion source as an anti-oxidant in pharmaceutical formulations.
    Type: Grant
    Filed: March 9, 2001
    Date of Patent: July 23, 2002
    Assignee: Pfizer Inc.
    Inventor: Hai Wang
  • Combination therapy
    Patent number: 6423705
    Abstract: The invention provdes methods of reducing tissue damage resulting from ischemia which comprise administering to a mammal in need of such reduction an effective amount of a combination, or a pharmaceutical composition comprising Such combination, of an NHE-1 inhibitor and a second compound selected from the group consisting of: (a) a complement modulator, (b) a metabolic modulator, (c) an anti-apoptotic agent, (d) a nitric oxide synthase-related agent, and (e) an enzyme/protein modulator.
    Type: Grant
    Filed: January 17, 2002
    Date of Patent: July 23, 2002
    Assignee: Pfizer Inc.
    Inventors: Wayne R. Tracey, Roger J. Hill
  • 4-(2-keto-1-benzimidazolinyl)piperidine compounds as ORL1-receptor agonists
    Patent number: 6423725
    Abstract: A compound of the formula: or the pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4 and R5 are defined above are useful as ORL1-receptor agonists, and useful as analgesics or the like in mammalian subjects.
    Type: Grant
    Filed: March 6, 2000
    Date of Patent: July 23, 2002
    Assignee: Pfizer INC
    Inventors: Fumitaka Ito, Hirohide Noguchi, Yoriko Ohashi, Hiroshi Kondo, Tatsuya Yamagishi
  • Combination treatment for depression, anxiety and psychosis
    Publication number: 20020094986
    Abstract: The present invention relates to a method of treating depression, anxiety or psychosis in a mammal, including a human, by administering to the mammal a D4 receptor antagonist in combination with an antidepressant or an anxiolytic agent. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier, a D4 receptor antagonist and an antidepressant or an anxiolytic agent.
    Type: Application
    Filed: December 5, 2001
    Publication date: July 18, 2002
    Applicant: Pfizer Inc
    Inventors: Phillip Branch Chappell, Stevin Howard Zorn
  • Crystalline therapeutic agent
    Patent number: 6420557
    Abstract: A polymorph of 1-{6-ethoxy-5-[3-ethyl-6,7-dihydro-2-(2-methoxyethyl)-7-oxo-2H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-pyridylsulfonyl}-4-ethylpiperazine.
    Type: Grant
    Filed: July 26, 2001
    Date of Patent: July 16, 2002
    Assignee: Pfizer Inc.
    Inventors: Laurence James Harris, Richard Anthony Storey, Albert Shaw Wood
  • 4?-substituted-9-deoxo-9a-aza-9a-homoerythromycin a derivatives
    Patent number: 6420536
    Abstract: The invention relates to a method of preparing compounds of the formula and to pharmaceutically acceptable salts thereof. The compounds of formula 1 are antibacterial agents that may be used to treat various bacterial and protozoa infections. The invention also relates to pharmaceutical compositions containing the compounds of formula 1 and to methods of treating bacterial protozoa infections by administering the compounds of formula 1. The invention also relates to methods of preparing the compounds of formula 1 and to intermediates useful in such preparation.
    Type: Grant
    Filed: November 18, 1999
    Date of Patent: July 16, 2002
    Assignee: Pfizer Inc
    Inventors: Brian Scott Bronk, Michael Anthony Letavic, Takushi Kaneko, Bingwei Vera Yang, Edward Alan Glazer, Hengmiao Cheng
  • Carbamate and carbazate ketolide antibiotics
    Patent number: 6420343
    Abstract: This invention relates to compounds of the formula 1 and to pharmaceutically acceptable salts, prodrugs and solvates thereof wherein X1, X2, R2 and R6 are as defined herein. The compounds of formula 1 are antibacterial and antiprotozoal agents that may be used to treat various bacterial and protozoal infections and disorders related to such infections. The invention also relates to pharmaceutical compositions containing the compounds of formula 1 and to methods of treating bacterial and protozoal infections by administering the compounds of formula 1.
    Type: Grant
    Filed: September 20, 1999
    Date of Patent: July 16, 2002
    Assignee: Pfizer Inc
    Inventors: Wei-Guo Su, Takushi Kaneko, Yong-Jin Wu
  • ARALKYL AND ARALKYLIDENE HETEROCYCLIC LACTAMS AND IMIDES
    Publication number: 20020091117
    Abstract: The present invention relates to compounds of the formula 1
    Type: Application
    Filed: November 6, 2001
    Publication date: July 11, 2002
    Applicant: Pfizer Inc.
    Inventor: Harry Ralph Howard
  • ARALKYL AND ARALKYLIDENE HETEROCYCLIC LACTAMS AND IMIDES
    Publication number: 20020091118
    Abstract: The present invention relates to compounds of the formula 1
    Type: Application
    Filed: November 6, 2001
    Publication date: July 11, 2002
    Applicant: Pfizer Inc.
    Inventor: Harry Ralph Howard
  • Aralkyl and aralkylidene heterocyclic lactams and imides
    Publication number: 20020091119
    Abstract: The present invention relates to compounds of the formula 1
    Type: Application
    Filed: November 6, 2001
    Publication date: July 11, 2002
    Applicant: Pfizer Inc.
    Inventor: Harry Ralph Howard
  • Methods of making quinoline amides
    Patent number: 6417367
    Abstract: The present invention relates to methods of making quinoline amides of Formula I below, which are microsomal triglyceride transfer protein inhibitors and can be used as medicines. The present invention also relates to compounds that are used to make quinoline amides of Formula I and methods of making these compounds.
    Type: Grant
    Filed: August 8, 2001
    Date of Patent: July 9, 2002
    Assignee: Pfizer Inc.
    Inventors: Norma J. Tom, David C. Whritenour
  • 5-substituted picolinic acid compounds production by Marasmiellus sp
    Patent number: 6416979
    Abstract: The present invention provides novel 5-substituted picolinic acid compounds of formula (I) or a pharmaceutically acceptable salt thereof: wherein R1 and R2 are independently H, C2-C6 acyl or halo-substituted benzoyl; and R3 is —C(O)O—C1-C6 alkyl, C(O)OH, CN, CONH2, CONHCH3, CON(CH3)2, 1-methyltetrazole or 2-methyltetrazole, with the proviso that when R2 is acetyl and R3 is methoxycarbonyl, R1 is not H; and that when R3 is CN, CONH2, CONHCH3, CON(CH3)2, 1-methyltetrazole or 2-methyltetrazole, R1 and R2 are H. The present invention also relates to a pharmaceutical composition comprising compound of the present invention, which is useful in the treatment of IL-1 and TNF mediated diseases or the like. The present invention further relates to a process for producing the compounds of the formula (I).
    Type: Grant
    Filed: September 8, 2000
    Date of Patent: July 9, 2002
    Assignee: Pfizer Inc.
    Inventors: Hideo Hirai, Katsuomi Ichikawa, Nakao Kojima, Hiroyuki Nishida, Kunio Satake, Nobuji Yoshikawa
  • &agr;-sulfonylamino hydroxamic acid inhibitors of matrix metalloproteinases for the treatment of peripheral or central nervous system disorders
    Patent number: 6417229
    Abstract: The present invention relates to a method of using a compound of the formula (I): wherein A, X1, X2 and Q are as defined herein, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, in the treatment of a disease, condition or disorder of the peripheral or central nervous system, including but not limited to Alzheimer's disease, stroke/cerebral ischemia, head trauma, spinal cord injury, multiple sclerosis, amyotrophic lateral sclerosis, Huntington's disease, Parkinson's disease, migraine, cerebral amyloid angiopathy, AIDS, age-related cognitive decline, mild cognitive impairment and prion diseases.
    Type: Grant
    Filed: September 27, 2000
    Date of Patent: July 9, 2002
    Assignee: Pfizer Inc
    Inventors: Barbara G. Sahagan, Anabella Villalobos
  • Quinolines and quinazolines useful in therapy
    Patent number: 6417194
    Abstract: Compounds of formula I, wherein R1 represents C1-4 alkoxy optionally substituted by one or more fluorine atoms; R2 and R3 independently represent H or C1-6 alkoxy (which is optionally substituted); R4 represents a 4-, 5-, 6- or 7-membered heterocyclic ring, the ring being optionally fused to a benzene ring or a 5- or 6-membered heterocyclic, the ring system as a whole being optionally substituted; X represents CH or N; and L is absent, or represents a cyclic group of formula Ia, or represents a chain of formula Ib, and pharmaceutically acceptable salts thereof; are useful in therapy, in particular in the treatment of benign prostatic hyperplasia.
    Type: Grant
    Filed: February 7, 2000
    Date of Patent: July 9, 2002
    Assignee: Pfizer, Inc.
    Inventors: David Nathan Abraham Fox, Alan John Collis, Simon John Mantell
  • Pyridylpyrrole compounds useful as interleukin-and TNF antagonists
    Patent number: 6417202
    Abstract: The present invention provides a compound of the formula: and its pharmaceutically acceptable salts, wherein R1, R2, R3, R4, R5 and m are as defined in claim 1. The present invention also provides processes for the preparation thereof, the use thereof in treating cytokines mediated diseases and/or cell adhesion molecules (CAMs) mediated diseases and pharmaceutical compositions for use in such therapy.
    Type: Grant
    Filed: December 10, 1999
    Date of Patent: July 9, 2002
    Assignee: Pfizer Inc.
    Inventors: Akiyoshi Kawai, Makoto Kawai, Yoshinori Murata, Junji Takada, Minoru Sakakibara
  • Antithrombotic agents
    Patent number: 6417203
    Abstract: Compounds of formula (I): are antithrombotic agents, having utility in a variety of therapeutic areas including the prevention and/or treatment of deep vein thrombosis (DVT) after surgery, major medical illness, paralysis, malignancy, prolonged immobilisation trauma, application of lower limb plaster casts, or fractures of the lower limbs or pelvis; recurrent DVT; DVT during pregnancy when there is a previous history thereof; reocclusion following thrombolytic therapy; chronic arterial obstruction; peripheral vascular disease; acute myocardial infarction; unstable angina; atrial fibrillation; thrombotic stroke; transient ischaemic attacks; disseminated intravascular coagulation; coagulation in extra-corporeal circuits; occlusion of arterio-venous shunts and blood vessel grafts (including coronary artery by-pass grafts); and restenosis and occlusion following angioplasty.
    Type: Grant
    Filed: September 14, 2000
    Date of Patent: July 9, 2002
    Assignee: Pfizer Inc.
    Inventors: Julian Blagg, Alan Daniel Brown, Elisabeth Colette Louise Gautier, Julian Duncan Smith, Andrew Brian McElroy
  • Fused bicyclic pyrimidine derivatives
    Patent number: 6413971
    Abstract: The invention relates to compounds of the formula and to pharmaceutically acceptable salts thereof, wherein R1, R2 and Z are as defined herein. The invention also relates to pharmaceutical compositions containing the compounds of formula I and to methods of using said compounds in the treatment of hyperproliferative diseases such as cancer.
    Type: Grant
    Filed: May 19, 1999
    Date of Patent: July 2, 2002
    Assignee: Pfizer Inc
    Inventors: Lee Daniel Arnold, Mikel Paul Moyer, Susan Beth Sobolov-Jaynes
  • Compositions and treatment for diabetic complications
    Patent number: 6413965
    Abstract: This invention is directed to methods, pharmaceutical compositions and kits comprising an aldose reductase inhibitor (ARI), a prodrug thereof or a pharmaceutically acceptable salt of said ARI or said prodrug and a selective COX-2 inhibitor, a prodrug thereof or a pharmaceutically acceptable salt of said selective COX-2 inhibitor or said prodrug. This invention further relates to methods of using those pharmaceutical compositions for the treatment of diabetic complications such as diabetic neuropathy, diabetic nephropathy, diabetic retinopathy and diabetic cardiomyopathy.
    Type: Grant
    Filed: June 23, 2000
    Date of Patent: July 2, 2002
    Assignee: Pfizer Inc.
    Inventor: Banavara L. Mylari